Novo Nordisk Expands Obesity Drug to Children Amid Market Hesitation
Novo Nordisk (NYSE:NVO) has reported promising results from its Phase 3 STEP Young trial, where semaglutide helped children aged six to twelve move below the clinical obesity threshold. Despite these findings and a consistent safety profile with prior data on semaglutide, NVO shares have fallen by nearly 17% over the past year. The potential for pediatric Wegovy labeling could extend Novo Nordisk's market reach beyond Eli Lilly’s tirzepatide, which has not yet targeted this age group. However, adoption faces challenges including payer resistance due to high drug costs and Medicaid coverage reductions in some states. Ethical concerns around administering chronic injectable drugs to young children also remain a hurdle. Analysts suggest that while pediatric obesity could become an expansion market for GLP-1 drugs like Wegovy, the process will likely be slow with adolescents being adopted first before younger age groups follow.
Topics: obesity drug pediatric use semaglutide stock performance Wegovy